Drug Discovery World
OCTOBER 27, 2022
Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital. Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Ageing causes stem cells to lose their normal structure by increased activity of the protein CDC42. [.].
Drug Discovery Today
OCTOBER 27, 2022
On October 26?27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Virginijus Šikšnys. The country now hosts the EMBL Partnership Institute for Genome Editing Technologies at the Vilnius University Life Sciences Center aiming to advance gene editing technologies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
OCTOBER 26, 2022
Bringing a psychedelic into a clinical trial setting is complex and requires a thorough operational approach to ensure the study’s success. Having worked in psychedelic research since the advent of industry-sponsored trials, Worldwide Clinical Trials has amassed the expertise needed to execute these studies successfully, recently sharing insights in a webinar titled “ Demystifying Complex Operations in Psychedelic Research ,” available on-demand now.
Antidote
OCTOBER 26, 2022
At Antidote, our mission is to connect patients with clinical trials using a data-driven, technological approach — and one of the ways we do that is through our clinical trial search engine, Antidote Match ™.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
OCTOBER 26, 2022
Kevin Holden. CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?
Drug Discovery Today
OCTOBER 28, 2022
Investment in purpose-built facilities supports ongoing recruitment and growth in new product development activities First phase of new facility doubles overall space capacity, with view to expand further as later stages of building complete
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Antidote
OCTOBER 24, 2022
IgA nephropathy, also known as Berger’s disease, refers to a buildup of protein in the kidneys that causes inflammation and damage. It is a chronic kidney disease that progresses over 10 to 20 years and can eventually lead to kidney failure.
Drug Discovery World
OCTOBER 24, 2022
Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models. . The new treatment completely eliminated tumours in 80% of mice across several model types, including those considered the most difficult to treat. . The approach combines traditional chemotherapy drugs with a new method for irradiating the tumour.
Drug Discovery Today
OCTOBER 27, 2022
On October 26?27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Virginijus Šikšnys. The country now hosts the EMBL Partnership Institute for Genome Editing Technologies at the Vilnius University Life Sciences Center aiming to advance gene editing technologies.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for OXBRYTA Oxbryta is a drug marketed by Global Blood Theraps and is included in two NDAs. There are nine patents protecting this drug. This drug…. The post New patent for Global Blood drug OXBRYTA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Crown Bioscience
OCTOBER 28, 2022
Major advances in breast cancer treatment have significantly improved survival rates, but metastatic disease continues to be the leading cause of breast cancer-related deaths. Developing novel therapies for metastatic breast cancer requires preclinical breast cancer models that better-recapitulate important clinical features of the disease, including metastasis.
Drug Discovery World
OCTOBER 24, 2022
Over three million people have been invited to join Our Future Health, which is set to become the UK’s largest ever health research programme. Letters are being sent out this autumn inviting members of the public to join Our Future Health, designed to help develop new ways to prevent, detect and treat diseases. Eventually, up to five million people will have the opportunity to join Our Future Health over the next few years, with the programme open to all UK adults.
Drug Channels
OCTOBER 28, 2022
Today’s guest post comes from Brooks Wildasin, Vice President of Product Management at CareMetx. Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Download CareMetx’s 2022 Report: The Evolving Landscape of Digital Healthcare Hubs to learn more about digital hub services and CareMetx’s solutions that improve the patient journey.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for SUNOSI Sunosi is a drug marketed by Axsome Malta and is included in one NDA. It is available from one supplier. There are nine patents…. The post New patent for Axsome Malta drug SUNOSI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Strateos Blog: Drug Discovery
OCTOBER 27, 2022
The collaborative spirit in the life sciences sector is at an all-time high. The unprecedented level of cooperation across academia, biopharmaceutical companies, solution providers, startups, and government agencies in the face of one of the biggest public health challenges in recent history, has proven what’s possible when we work towards a common goal.
Drug Discovery World
OCTOBER 28, 2022
A potential new treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been validated for scientific evaluation under an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP). . Pharming’s investigational drug leniolisib, a selective phosphoinositide 3-kinase delta (PI3K?) inhibitor, will be evaluated as a therapy in adolescents and adults 12 years or older. .
Translation
OCTOBER 26, 2022
Leading packaging providers, an innovative American biotech company, and a biomaterials research company join Halo to bring new innovations to the world and move science forward. We are delighted to welcome four new customers to Halo’s platform: Amcor Limited, a global producer of sustainable packaging; Altium Packaging, a leading packaging solutions provider; Ginkgo Bioworks, an American biotechnology company specializing in genetic engineering; and one.five, a biomaterials research company.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for IBSRELA Ibsrela is a drug marketed by Ardelyx Inc and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Ardelyx Inc drug IBSRELA appeared first on DrugPatentWatch - Make Better Decisions.
Nvidia Developer: Drug Discovery
OCTOBER 24, 2022
A virtual event designed for healthcare developers and startups, this summit on November 10, 2022 offers a full day of technical talks to reach developers and. A virtual event designed for healthcare developers and startups, this summit on November 10, 2022 offers a full day of technical talks to reach developers and technical leaders in the EMEA region.
Drug Discovery World
OCTOBER 28, 2022
A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer. . The team successfully used a combination of tyrosine kinase inhibitors, opening up new avenues for developing therapies that are more targeted than chemotherapy. . Colorectal cancer is one of the most common cancers. Over time, chemotherapy induces resistance in most patients, who end up being unresponsive to the drugs.
Antidote
OCTOBER 24, 2022
We often reference our patient database: 400,000+ patients who have raised their hands to take part in medical research and shared health data to help us determine eligibility. The beauty of the Antidote database is that it provides a real-word picture of true patient populations — their demographic information as well as health details such as conditions they have, medications they’re on, and condition-specific details.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for RYDAPT Rydapt is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent expiration for Novartis drug RYDAPT appeared first on DrugPatentWatch - Make Better Decisions.
The Premier Consulting Blog
OCTOBER 24, 2022
The Marketing Authorization (MA) holder for a treatment for onychomycosis, having previously secured regulatory approval in several markets, sought to introduce the product to the European market. Completion of the Marketing Authorization Application (MAA) required utilization of the Active Substance Master File (ASMF) procedure, which is designed to facilitate evaluation of the suitability of the use of the active substance in the medicinal product.
Drug Discovery World
OCTOBER 27, 2022
Cancers can evolve to become more aggressive without relying only on DNA mutations, two major studies have revealed. . The research characterises an extra level of control of cancer gene activity within tumours, which the researchers describe as cancer’s ‘dark matter’. . The two studies showed how a level of gene control called ‘epigenetics’ plays a central role in the development and progression of bowel cancer.
Drug & Device Law
OCTOBER 26, 2022
More plaintiffs, more money. And we don’t mean a mere linear increase. If, as Hegel said, quantitative differences ultimately become qualitative differences, in litigation that happens when going from one plaintiff to two, and certainly to several or many. When a jury sees multiple people bringing claims against a defendant, they think something’s up, where there’s smoke there’s fire, and the defendant must have done something wrong.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for ZONISADE Zonisade is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. The generic ingredient in ZONISADE…. The post New patent for Azurity drug ZONISADE appeared first on DrugPatentWatch - Make Better Decisions.
The Premier Consulting Blog
OCTOBER 26, 2022
During the development cycle of a regulated therapeutic, the transfer of the manufacturing process is inevitable. The process will be transferred from the development lab to a pilot or small-scale manufacturing facility and, if the program is successful, to a facility for commercial manufacturing. With each transfer, important information needs to be readily available to the receiving party to ensure the required utilities, facilities, and equipment are available for the successful implementatio
Drug Discovery World
OCTOBER 27, 2022
Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold purpose of profitability and societal advancement to the cell and gene therapy industry.
Drug & Device Law
OCTOBER 27, 2022
The case we discuss today, Vaughan v. Biomat USA, Inc. , 2022 WL 4329094 (N.D. Ill. 2022), is neither a medical-device nor a pharmaceutical case. Nor is it a product-liability case. It is, however, a preemption case that implicates two issues relevant to our world. The plaintiffs sold blood plasma to the defendants. When they did so, the defendants required them to scan their fingerprints for identification and tracking.
Drug Patent Watch
OCTOBER 28, 2022
Annual Drug Patent Expirations for EMERPHED Emerphed is a drug marketed by Nexus Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Nexus Pharms drug EMERPHED appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery World
OCTOBER 27, 2022
This is the latest episode of the free DDW podcast, “The role of animals in the future of drug discovery”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “ How an animal model provider can save your resources ” and “ Hype or hope – microphysiological systems? ”.
Drug Discovery World
OCTOBER 27, 2022
This is the latest episode of the free DDW podcast, “The role of animals in the future of drug discovery”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “ How an animal model provider can save your resources ” and “ Hype or hope – microphysiological systems? ”.
Drug Discovery World
OCTOBER 26, 2022
A study by the Qatar Genome Research Consortium, led by Dr Lotfi Chouchane from Weill Cornell Medicine-Qatar, has reported the first landscape of cancer germline mutations – hereditary mutations – in the Qatari population. . Since then, scientists at Qatar Foundation’s (QF) Qatar Genome Programme (QGP) have teamed up with clinicians at Hamad Medical Corporation (HMC) to build on these findings, using them to inform the current standard of care in the country. .
Drug Discovery World
OCTOBER 26, 2022
An international team of scientists have engineered protein banana lectin, or BanLec, to create a new version that can fight off a range of viruses without unwanted side effects. . The genetically engineered version has been called H84T and worked against the viruses that cause AIDS, hepatitis C and influenza in tests in tissue and blood samples. .
Expert insights. Personalized for you.
246 
Let's personalize your content